Anebulo Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

9 Months Ended

Mar. 31, 2023

Note 4. Accrued Expenses

Accrued expenses consisted of the following:

Schedule of Accrued Expenses


	March 31, 2023		June 30, 2022
Accrued research and development	$	591,434	$	105,980
Accrued payroll related expenses		297,999		25,723
Accrued audit expenses		30,750		-
Total accrued expenses	$	920,183	$	131,703